MNPR
NASDAQMonopar Therapeutics Inc.
Website
News25/Ratings12
News · 26 weeks41-29%
2025-10-262026-04-19
Mix1590d
- Insider5(33%)
- SEC Filings5(33%)
- Other3(20%)
- Leadership1(7%)
- Offering1(7%)
Latest news
25 items- SECMonopar Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Monopar Therapeutics (0001645469) (Filer)
- PRMonopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026WILMETTE, Ill., April 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, announced new analyses from the randomized controlled Phase 3 FoCus trial of ALXN1840 (tiomolibdate choline, TMC) showing greater neurologic benefit versus standard of care (SoC) in Wilson disease patients with neurologic symptoms at baseline. The data will be presented today at the American Academy of Neurology (AAN) Annual Meeting 2026, taking place April 18-22, 2026. In a late-breaker oral and poster presentation titled "Greater clinical benefit with t
- INSIDERSEC Form 4 filed by Robinson Chandler4 - Monopar Therapeutics (0001645469) (Issuer)
- INSIDERSEC Form 4 filed by Cittadine Andrew4 - Monopar Therapeutics (0001645469) (Issuer)
- SECAmendment: SEC Form 10-K/A filed by Monopar Therapeutics Inc.10-K/A - Monopar Therapeutics (0001645469) (Filer)
- SECMonopar Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Monopar Therapeutics (0001645469) (Filer)
- SECSEC Form 10-K filed by Monopar Therapeutics Inc.10-K - Monopar Therapeutics (0001645469) (Filer)
- PRMonopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business UpdateWILMETTE, Ill., March 27, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar," the "Company," "we") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the fourth quarter and full-year 2025 financial results and provided a summary of recent developments. "2025 was a productive year for Monopar, marked by multiple ALXN1840 data presentations, an important publication, a strengthened balance sheet and continued progress toward a planned New Drug Application submission for ALXN1840 in Wilson disease," said Chandler Robinson, MD, Chief Executive Officer of Monopar. "We also recently strengt
- INSIDERSEC Form 4 filed by CCSO Rodriguez Susan4 - Monopar Therapeutics (0001645469) (Issuer)
- INSIDERSEC Form 3 filed by new insider Rodriguez Susan3 - Monopar Therapeutics (0001645469) (Issuer)
- SECMonopar Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Monopar Therapeutics (0001645469) (Filer)
- PRMonopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy OfficerWILMETTE, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR) ("Monopar" or the "Company"), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the appointment of Susan Rodriguez as Chief Commercial and Strategy Officer, effective immediately. In this newly created executive role, Ms. Rodriguez will lead the Company's commercial strategy and infrastructure build-out as Monopar prepares for the planned submission of a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") in the first half of 2026 for ALXN1840, its late-stage investigational therapy for Wilson d
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Monopar Therapeutics Inc.SCHEDULE 13G/A - Monopar Therapeutics (0001645469) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Monopar Therapeutics Inc.SCHEDULE 13G/A - Monopar Therapeutics (0001645469) (Subject)
- INSIDERChief Executive Officer Robinson Chandler acquired 62,815 shares (SEC Form 4)4 - Monopar Therapeutics (0001645469) (Issuer)
- ANALYSTMorgan Stanley initiated coverage on Monopar Therapeutics with a new price targetMorgan Stanley initiated coverage of Monopar Therapeutics with a rating of Overweight and set a new price target of $115.00
- INSIDERChief Executive Officer Robinson Chandler converted options into 8,724 shares and covered exercise/tax liability with 2,558 shares, increasing direct ownership by 8% to 85,718 units (SEC Form 4)4 - Monopar Therapeutics (0001645469) (Issuer)
- INSIDERChief Operating Officer Cittadine Andrew converted options into 4,326 shares and covered exercise/tax liability with 1,889 shares, increasing direct ownership by 5% to 50,726 units (SEC Form 4)4 - Monopar Therapeutics (0001645469) (Issuer)
- INSIDERSEC Form 4 filed by Acting Chief Medical Officer Rioux Patrice4 - Monopar Therapeutics (0001645469) (Issuer)
- INSIDERChief Financial Officer Vu Quan Anh bought $104,925 worth of shares (1,500 units at $69.95) (SEC Form 4)4 - Monopar Therapeutics (0001645469) (Issuer)
- SECSEC Form 144 filed by Monopar Therapeutics Inc.144 - Monopar Therapeutics (0001645469) (Subject)
- INSIDERDirector Klausner Arthur J sold $343,889 worth of shares (5,121 units at $67.15), decreasing direct ownership by 37% to 8,762 units (SEC Form 4)4 - Monopar Therapeutics (0001645469) (Issuer)
- INSIDERLarge owner Hendricks Diane disposed of 43,499 shares (SEC Form 4)4 - Monopar Therapeutics (0001645469) (Issuer)
- INSIDERDirector Klausner Arthur J acquired 7,710 shares, increasing direct ownership by 125% to 13,883 units (SEC Form 4)4 - Monopar Therapeutics (0001645469) (Issuer)
- INSIDERSEC Form 4 filed by Chief Operating Officer Cittadine Andrew4 - Monopar Therapeutics (0001645469) (Issuer)